Tonix Pharmaceuticals (TNXP) saw its stock surge 5.74% in a 24-hour period during Friday's trading session, despite reporting mixed second-quarter results. The biotechnology company's shares demonstrated resilience in the face of earnings that missed analyst expectations.

For the quarter ended June 30, Tonix reported a loss of $3.86 per share, wider than the average analyst estimate of a $3.21 loss. Revenue also fell short, declining 9.5% year-over-year to $2.00 million, below the expected $2.43 million. However, investors seemed to look past these immediate numbers, focusing instead on the company's potential and analyst sentiment.

The market's positive reaction may be attributed to several factors. Analysts maintain a "buy" rating on Tonix shares, with a median 12-month price target of $65.00, suggesting a potential upside of about 5.3% from its last closing price. Additionally, Tonix's stock has shown impressive performance, rising 71.1% this quarter and 86.7% year-to-date. This broader context of growth and analyst confidence appears to be outweighing the short-term earnings miss, driving the stock's significant intraday gain.